文献速递类风湿关节炎

英国两个多中心早期类风湿关节炎队列25年间影像学进展减少及类风湿因子贡献变化

Reductions in Radiographic Progression in Early Rheumatoid Arthritis Over Twenty-Five Years: Changing Contribution From Rheumatoid Factor in Two Multicenter UK Inception Cohorts.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2017-11-06

研究比较了1986-2001年ERAS与2002-2013年ERAN两个早期类风湿关节炎队列的5年影像学进展,发现ERAN患者基线Sharp/van der Heijde评分更低(6.2 vs 10.5),年变化率更慢(2.5 vs 6.9/年),且类风湿因子对进展的预测作用在现代治疗背景下明显减弱。

要点

  • ERAN队列基线总SHS评分和年变化率均显著低于ERAS队列。
  • RF阳性在ERAS中与更快进展相关,在ERAN中差异无统计学意义。

核心结论

  • 两个早期RA队列间影像学进展显著减少,与基线损伤更低及早期DMARD使用变化等因素相关。
  • RF作为影像学进展预后标志物的影响在现代治疗背景下已明显减弱。

研究设计与样本

  • 研究纳入ERAS(1986-2001)和ERAN(2002-2013)两个多中心早期类风湿关节炎队列,采用Sharp/van der Heijde法记录影像学关节损伤。
  • 使用混合效应负二项回归估计5年内影像学损伤变化,分别分析侵蚀和关节间隙狭窄,并控制RF、年龄、性别和基线疾病活动标志物。

主要发现

  • ERAS有1216例、ERAN有446例患者具有影像学数据。
  • ERAN基线平均总SHS评分低于ERAS(6.2 vs 10.5;P < 0.001),平均年变化率也更低(2.5/年 vs 6.9/年;P < 0.001)。
  • ERAN基线评分较低主要源于关节间隙狭窄减少(ERAS 3.9 vs ERAN 1.2;P < 0.001)及侵蚀减少(ERAS 1.9 vs ERAN 0.8;P < 0.001)。
  • RF在兩個队列中均与更大进展相关,但RF阳性者平均年变化率的绝对差异在ERAS中更高(RF阳性8.6 vs RF阴性5.1;P < 0.001),在ERAN中差异无统计学意义(RF阳性2.0 vs RF阴性1.9;P = 0.855)。

临床怎么用

  • 现代治疗背景下,早期RA患者影像学进展已显著减少,RF状态对进展的预测价值下降,临床决策应综合评估而非仅依赖RF。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the 5-year progression of erosions and joint space narrowing (JSN) and their associations with rheumatoid factor (RF) status in 2 large, multicenter, early rheumatoid arthritis cohorts, spanning 25 years. METHODS: Radiographic joint damage was recorded using the Sharp/van der Heijde (SHS) method in the Early Rheumatoid Arthritis Study (ERAS), 1986-2001, and the Early Rheumatoid Arthritis Network (ERAN), 2002-2013. Mixed-effects negative binomial regression estimated changes in radiographic damage over 5 years, including erosions and JSN, separately. RF, along with age, sex, and baseline markers of disease activity were controlled for. RESULTS: A total of 1,216 patients from ERAS and 446 from ERAN had radiographic data. Compared to ERAS, ERAN patients had a lower mean total SHS score at baseline (ERAN 6.2 versus ERAS 10.5; P < 0.001) and mean annual rate of change (ERAN 2.5 per year versus ERAS 6.9 per year; P < 0.001). Seventy-four percent of ERAS and 27% of ERAN patients progressed ≥5 units. Lower scores at baseline in ERAN were largely driven by reductions in JSN (ERAS 3.9 versus ERAN 1.2; P < 0.001), along with erosions (ERAS 1.9 versus ERAN 0.8; P < 0.001). RF was associated with greater progression in each cohort, but the absolute difference in mean annual rate of change for RF-positive patients was substantially higher for ERAS (RF positive 8.6 versus RF negative 5.1; P < 0.001), relative to ERAN (RF positive 2.0 versus RF negative 1.9; P = 0.855). CONCLUSION: Radiographic progression was shown to be significantly reduced between the 2 cohorts, and was associated with lower baseline damage and other factors, including changes in early disease-modifying antirheumatic drug use. The impact of RF status as a prognostic marker of clinically meaningful change in radiographic progression has markedly diminished in the context of more modern treatment.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Carpenter L, Norton S, Nikiphorou E, et al. Reductions in Radiographic Progression in Early Rheumatoid Arthritis Over Twenty-Five Years: Changing Contribution From Rheumatoid Factor in Two Multicenter UK Inception Cohorts. Arthritis Care Res (Hoboken). 2017. PMID: 28217885. doi:10.1002/acr.23217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。